Saturday 17 October 2026
Export KZIA’s income statement to Excel — free account
Novogen Limited
KZIA Healthcare Biotechnology
Novogen Limited’s revenue for fiscal 2025 (year ended June 2025) was $1.2 million, down 24.7% from fiscal 2024.
7.25
0.15
−2.03%
Follow KZIA
| Dec '25 | Jun '25 | Dec '24 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
2.86 | 0.32 | 0.19 | 0.22 | |
Current Ratio |
2.87 | 0.35 | 0.21 | 0.24 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.14% | 6.52% | 0.79% | 2.94% | |
Debt/Equity |
0.00 | (0.05) | (0.04) | (0.06) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Intangible Assets out of Total Assets |
0.02 | 0.18 | 0.81 | 0.71 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | |
Free Cash Flow Yield |
— | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(6.26) | (8.60) | (5.49) | (6.28) | |
Working Capital |
29.94 | (5.91) | (8.54) | (12.89) | |
Capital Expenditures |
— | 0.00 | — | 0.00 | |
Net Current Asset Value |
29.76 | (6.11) | (11.93) | (16.69) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Receivables |
1.32 | 1.34 | 0.27 | 1.31 | |
Average Payables |
5.12 | 4.73 | 4.44 | 6.30 | |
Average Assets |
31.28 | 11.42 | 14.99 | 19.76 | |
Average Common Equity |
16.97 | 1.37 | 2.57 | 3.48 |
Columns are period end dates · fundamentals updated 2 Oct 2026